Compare WIT & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WIT | INSM |
|---|---|---|
| Founded | 1945 | 1988 |
| Country | India | United States |
| Employees | 242021 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.3B | 35.2B |
| IPO Year | 2000 | 2000 |
| Metric | WIT | INSM |
|---|---|---|
| Price | $2.31 | $140.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 23 |
| Target Price | N/A | ★ $188.73 |
| AVG Volume (30 Days) | ★ 11.8M | 2.1M |
| Earning Date | 01-01-0001 | 05-21-2026 |
| Dividend Yield | ★ 4.93% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.75 | $168.46 |
| Revenue Next Year | $6.67 | $65.97 |
| P/E Ratio | $16.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.11 | $60.40 |
| 52 Week High | $3.24 | $212.75 |
| Indicator | WIT | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 46.75 | 34.85 |
| Support Level | N/A | $139.81 |
| Resistance Level | $2.86 | $167.01 |
| Average True Range (ATR) | 0.07 | 6.70 |
| MACD | 0.02 | -0.57 |
| Stochastic Oscillator | 81.67 | 0.58 |
Wipro is a multinational IT services provider based in Bengaluru, India. The company pivoted into the IT space in the 1980s and grew into one of the largest Indian IT consulting companies during the dot-com boom. Nowadays, Wipro leverages its offshore outsourcing model to derive a significant portion of its revenue from North America and Europe.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.